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coronary vein without IABP counterpulsa-
tion.
Our article1 does not support the idea of
coronary venous arterialization. We did not
ligate the cardiac vein distally to isolate the
arterialized venous system from the rest of
the venous anatomy and to prevent steal
through the coronary sinus to the right
atrium, as is performed in surgical or per-
cutaneous arterialization of the coronary
venous system. However, even in the pres-
ence of the steal to the right atrium, the
flow pattern of the arteriovenous graft we
demonstrated may give the readers some
suggestions regarding the physiology of the
arterialized coronary venous system.
To be exact, the main finding of our
article1 is that it is impossible to detect
incorrect grafting of the LITA to the coro-
nary vein by flow waveform analysis with
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Difficulty of early diagnosis in
patients with solitary pulmonary
nodule
To the Editor:
We would like to express our opinion
about the article by Crestanello and as-
sociates.1 First, we congratulate them for
the well-performed study contributing to
the early diagnosis of lung cancer. Be-
cause an early diagnosis is likely to lead
to better survival, it is necessary to find a
useful, easy, low-cost method to obtain
better survival in patients with non–small
cell lung cancer. But the results of this
study seem to indicate that low-dose
computed tomography (CT) screening is
not the gold standard to obtain an early
diagnosis. Low-dose CT screening in a
well-selected group of patients detects a
large number of indeterminate pulmonary
nodules, but the diagnosis is not always
made in the early stage; 7 patients
(14.5%) had advanced lung cancer in
stage IIIA or greater. These patients had
a late diagnosis, despite an excellent
treatment algorithm and a retrospective
analysis of previous thorax CT. The per-
centage of patients with advanced lung
cancer is very high for a well-selected
group of patients, how is relatively high
(39%) the percentage of benign nodules
submitted to surgical operation.2 Discus-
sants emphasized that the main problem
remains in detecting nodules less than 1
cm in diameter, whereas fortunately no
discussion is necessary on the detection
of nodules larger than 2 cm.
What is meant by the authors’ state-
ment, “morphologic appearance worrisome
for cancer”?
Did the authors consider ground-glass
opacity or other CT pattern? In their study,
did the authors investigate the presence of
ground-glass opacity3 in nodules less than
1 cm in diameter? Some recent studies
have established a correlation between this
CT pattern and the possibility of a malig-
nant pulmonary nodule. If they studied this
pattern, was the correlation observed in 37
nodules less than 1 cm in diameter in the
patients enrolled in their study?
Last, what do the authors think about a
computer-aided diagnosis and serial CT
scan? These 2 methods have been proposed
to distinguish between benign and malig-
nant nodules.4,5 The computer-aided pro-
gram can predict the histology of solitary
pulmonary nodules by means of a simple
chest x-ray film, whereas the serial CT scan
algorithm enables volumetric modeling and
may permit accurate assessment of dou-
bling time over a relatively short period (20
days).
In conclusion, we believe that low-dose
CT alone is not adequate to screen for
solitary pulmonary nodules because it is
possible to miss an early diagnosis and
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Reply to the Editor:
We appreciate Sortini and colleagues’
comments concerning our report regarding
surgical intervention in patients enrolled in
a computed tomography (CT) screening
trial. The radiographic finding in nodules
that we considered worrisome for cancer
include spiculation, noncalcification, diam-
eter greater than 7 mm, and enlargement on
serial examination.
The question about ground-glass opac-
ities observed on CT is important. Our cur-
rent policy is to carefully observe ground-
glass opacities that are less than 7.0 mm in
diameter. If they enlarge, we would either
perform a percutaneous needle biopsy or
thoracoscopic wedge resection of the nod-
ule to establish a histologic diagnosis.
Our report included 16 patients in the
surgical group with ground-glass opacities.
Six of these patients had nodules that were
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smaller than 1.0 cm; the stage was IA in 5
patients and IIIA in 1 patient. For the entire
16 patients with ground-glass opacities, the
stage was IA in 13, IB in 1, and IIIA in 2.
Our report, however, only examined those
patients who underwent surgical interven-
tion, so it does not represent a complete
description of all patients in our CT screen-
ing trial with ground-glass opacities. We
eagerly await continued reporting from the
radiology literature about the entire spec-
trum of patients found to have ground-glass
opacity on a screening CT.
The question regarding computer-aided
diagnosis for enlargement of small nodules is
provocative. Three-dimensional computer-
aided diagnosis is clearly superior to 2-
dimensional human measurement. This
would be the preferred technique only when
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Why clopidogrel failed to inhibit
platelet function early after coronary
artery bypass surgery: To load or not
to load, and is it a question of
resistance?
To the Editor:
Antiplatelet therapy remains a topic of
much-deserved attention and debate. We
read with interest the recent article by Lim
and associates1 in which they found that
clopidogrel after coronary artery bypass
grafting failed to inhibit platelet function,
on the basis of the percentage platelet ag-
gregation on day 5. Patients were random-
ized to receive 100 or 325 mg of aspirin
daily or 75 mg of clopidogrel daily for 5
days after coronary artery bypass grafting.
It is not clear whether patients in the clo-
pidogrel arm received a loading dose be-
fore the daily maintenance dose. Several
similar studies assessing platelet inhibition,
albeit in the context of percutaneous coro-
nary intervention, have demonstrated the
importance of appropriate loading of 300 to
600 mg if steady-state levels of platelet
aggregation are to be achieved within the
first 24 hours.2-4 Daily maintenance dosing
with 75 mg of clopidogrel without preload-
ing, as in this study, has been shown to
result in steady-state levels of platelet in-
hibition only after 3 to 7 days.5
The second observation with regard to
this study is that the investigators did not
state whether a baseline pretreatment sam-
ple was taken before surgery or before ad-
ministration of the antiplatelet therapy.
Whether this would have added much to
the final analysis remains unclear, but evi-
dence, again drawn from studies in the
percutaneous coronary intervention setting,
have suggested pretreatment platelet reac-
tivity to be an important determinant of
posttreatment reactivity.6
The final comment is the most elusive,
namely, the issue of “clopidogrel resis-
tance.” Although it was not directly men-
tioned by the authors, we can assume that it
was alluded to in their discussion. It is
likely that a correlation exists between a
laboratory measure of clinical clopidogrel
nonresponsiveness and the clinical out-
come. However, until such time as there is
greater understanding of the likely mecha-
nisms of clopidogrel responsiveness and the
individual heterogeneity that is apparent, can
we totally dismiss the efficacy of clopidogrel
in the early postoperative period?
Ian Hunt, MRCSa
Lucy J. H. Blows, MRCPb
Sundip J. Patel, MRCPb
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Reply to the Editor:
In our reply to Raja, we have addressed a
similar query with regard to the dosing
regimen of clopidogrel. It is vitally impor-
tant to appreciate that the study in which
Hunt and associates quote the time to the
onset of the effects of clopidogrel (4 to 7
days) is from a sample of healthy subjects.1
Nonrandomized studies after coronary ar-
tery bypass surgery suggest that it takes 9
to 28 days.2 Our results are consistent with
the latter.
In our article, you will note that we
reported all measurements as the percent-
age change compared with baseline.3 The
baseline sample was taken on the day be-
fore surgery.
We respectfully disagree with the final
comment of Hunt. A previous observa-
tional study and our randomized data are
consistent regarding the inefficacy of clo-
pidogrel early after coronary surgery as-
sessed on aggregometry. At present, we are
unaware of any evidence to the contrary;
therefore, the onus should be to prove that
an effect exists before prescribing clopi-
dogrel (as the sole antiplatelet in this time
frame), rather than subjecting patients to
the possibility of ineffective treatment
while awaiting a “greater understanding of
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